Covid19, Intensive Care Unit Delirium, Post Intensive Care Unit Syndrome
Conditions
Brief summary
The global pandemic caused by the SARS-CoV-2 virus is confronting the German health system with a novel pathogen. This means that a timely evaluation of all available results is required. In the field of intensive care in particular, there are significant gaps in knowledge, particularly with regard to delirium. In this respect, this study also serves directly to investigate the pathways of delirium outcome in COVID-19 patients.
Interventions
None listed
Sponsors
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients with SARS-CoV-2 positive Covid-19 disease * Age≥18 years * Proven by positive PCR tests from nasal/ throat swabs as well as samples from the deep respiratory tract. * Period 01.01.2020 to 21.02.2022
Exclusion criteria
* NONE
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of delirium | 01.01.2020 - 21.02.2022 | Delirium is measured by validated screening scores. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient characteristics | 01.01.2020 - 21.02.2022 | Patient characteristics at hospital admission e.g. score level |
| Blood gas analysis | 01.01.2020-31.07.2020 | Monitoring of blood gas analysis |
| Enteral nutrition | 01.01.2020-31.07.2020 | Monitoring of enteral nutrition |
| Parenteral nutrition | 01.01.2020 - 21.02.2022 | Monitoring of parenteral nutrition |
| Serum albumin | 01.01.2020 - 21.02.2022 | Monitoring of serum albumin level |
| Total protein | 01.01.2020 - 21.02.2022 | Monitoring of total protein level |
| Phosphate | 01.01.2020 - 21.02.2022 | Monitoring of phosphate levels |
| Triglyceride | 01.01.2020 - 21.02.2022 | Monitoring of triglyceride levels |
| Caloric intake | 01.01.2020 - 21.02.2022 | Caloric intake is measured by total daily energy supply. |
| Respiratory setting | 01.01.2020 - 21.02.2022 | Respiratory factors are measured respiratory setting |
| Inflammatory laboratory parameter 1 | 01.01.2020 - 21.02.2022 | Monitoring of interleukine level |
| Risk factors for severe COVID-19 | 01.01.2020 - 21.02.2022 | Risk factors are defined according to actual literature e.g. obesity, diabetes or hypertension. |
| Inflammatory laboratory parameter 3 | 01.01.2020 - 21.02.2022 | Monitoring of big immune status |
| Inflammatory laboratory parameter 4 | 01.01.2020 - 21.02.2022 | Monitoring of t-cell population |
| Toxic-drug factors | 01.01.2020 - 21.02.2022 | Toxic-drug factors are measured by concomitant medication. |
| Sociodemographic factors | 01.01.2020 - 21.02.2022 | Sociodemographic factors are measured by Audit, Fagerström, occupation, age, gender, cognitive status. |
| Breathing hours | 01.01.2020 - 21.02.2022 | Breathing hours are measured by non-invasive and invasive ventilation. |
| Length of intensive care unit stay | 01.01.2020 - 21.02.2022 | Length of intensive care unit stay is measured in days of stay in the intensive care unit. |
| Length of hospital stay | 01.01.2020 - 31.07.2022 | Length of hospital stay is measured in days of stay in hospital. |
| Adverse events | 01.01.2020 - 21.02.2022 | Adverse Events defined by thromboembolic events, nosocomial infections, septic shock, acute renal failure, heart attack, post-intensive care syndrome and death are recorded until hospital discharge. |
| Post Intensive Care Unit Syndrome (PICS) | 01.01.2020 - 21.02.2022 | Post Intensive Care Unit Syndrome (PICS) is measured by a validated battery (composite endpoint). |
| In-hospital mortality | 01.01.2020 - 21.02.2022 | Mortality is measured in the hospital |
| Mortality | 01.01.2020 - 31.08.2022 | Mortality is measured until 180 days |
| Inflammatory laboratory parameter 2 | 01.01.2020 - 21.02.2022 | Monitoring of cytokine level |
Countries
Germany
Outcome results
None listed